Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH.
Patients with cancer have an increased risk of thrombosis requiring anticoagulants and/or antiplatelet agents, and they can also encounter thrombocytopenia due to cancer itself or cancer therapies. They often undergo many procedures such as tissue or bone marrow biopsies, placement of central access lines, diagnostic or therapeutic draining procedures, lumbar puncture, and more. Management of antithrombotic agents or thrombocytopenia around the time of these procedures is highly variable. In this document, the Hemostasis and Malignancy Subcommittee of the International Society on Thrombosis and Haemostasis aims to provide useful practice guidance in the management of antithrombotic agents and thrombocytopenia around the time of common procedures in patients with cancer.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Thrombosis
- Thrombocytopenia
- Platelet Aggregation Inhibitors
- Neoplasms
- Humans
- Fibrinolytic Agents
- Cardiovascular System & Hematology
- Anticoagulants
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Thrombosis
- Thrombocytopenia
- Platelet Aggregation Inhibitors
- Neoplasms
- Humans
- Fibrinolytic Agents
- Cardiovascular System & Hematology
- Anticoagulants
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology